2025
Impact of peritoneal macrophage depletion on endometriotic lesion development in a mouse model
Stratopoulou C, Cacciottola L, Gawde N, Ngombo A, Brusa D, Donnez J, Taylor H, Dolmans M. Impact of peritoneal macrophage depletion on endometriotic lesion development in a mouse model. Journal Of Endometriosis And Uterine Disorders 2025, 10: 100113. DOI: 10.1016/j.jeud.2025.100113.Peer-Reviewed Original ResearchMacrophage depletionEndometriotic lesionsTreated miceMacrophage accumulationMouse modelVascular endothelial growth factor immunostainingEndometriosis developmentQuantification of immune cellsFlow cytometryMouse model of endometriosisClodronate-containing liposomesKi67-positive proliferating cellsNovel therapeutic optionsRate of fibrosisModel of endometriosisTUNEL-positive apoptotic cellsLevels of fibrosisPathogenesis of endometriosisReproductive-age womenMasson's trichrome stainingEndometriotic lesion developmentEnhanced cell deathPlacebo-ControlledUterine fragmentsT cellsQuinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse events
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply